RETIN-A-MICRO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for RETIN-A-MICRO (RETIN-A-MICRO).
Retinoid agonist that binds to and activates retinoic acid receptors (RARs), modulating gene expression involved in cell proliferation, differentiation, and keratinization, leading to normalization of follicular keratinization and reduced comedone formation.
| Metabolism | Primarily metabolized in the skin via oxidation; systemic metabolism involves hepatic cytochrome P450 enzymes (including CYP2C8, CYP2C9, CYP2C19, and CYP3A4) and isomerization to various metabolites. |
| Excretion | Tretinoin is metabolized in the liver via CYP450 enzymes, primarily CYP2A6 and CYP3A4. Metabolites are eliminated via bile and feces (approximately 60%) and urine (approximately 30%), with less than 1% of unchanged drug excreted renally. |
| Half-life | Terminal elimination half-life is approximately 0.5-2 hours after topical application, though prolonged due to slow release from microsphere formulation. Clinical context: rapid clearance limits systemic accumulation. |
| Protein binding | >95% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Not well characterized for topical formulation; systemic absorption is minimal (<0.5% of applied dose). Intravenous tretinoin Vd is approximately 0.3 L/kg, indicating limited extravascular distribution. |
| Bioavailability | Topical bioavailability is negligible (<0.5%) due to extensive cutaneous metabolism and low absorption; oral tretinoin bioavailability is approximately 50% (not a route for Retin-A Micro). |
| Onset of Action | 2-4 weeks for visible reduction in acne lesions with topical microsphere gel; earlier improvement may be seen in comedones. |
| Duration of Action | Sustained release from microspheres provides 24-hour drug delivery; clinical benefit persists with continued use. Effects on acne may last weeks after discontinuation due to retinoid remodeling. |
Topical, apply a pea-sized amount to the entire face once daily at bedtime.
| Dosage form | GEL |
| Renal impairment | No adjustment required. |
| Liver impairment | No adjustment required. |
| Pediatric use | Approved for acne vulgaris in patients aged 9 years and older; apply a pea-sized amount topically once daily at bedtime. |
| Geriatric use | Use with caution due to increased skin fragility and potential for irritation; consider lower strength or less frequent application. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for RETIN-A-MICRO (RETIN-A-MICRO).
| Breastfeeding | No data on M/P ratio. Systemic absorption after topical application is <2% in adults; negligible transfer to breast milk expected. Use with caution; manufacturer advises discontinuation of nursing or drug based on importance of therapy. Avoid application to breast area. |
| Teratogenic Risk | Category C. First trimester: Topical use may be associated with rare congenital anomalies (e.g., CNS defects, cardiovascular malformations) based on case reports; systemic absorption is minimal but risk cannot be excluded. Second trimester: Avoid use due to potential fetal retinoid toxicity. Third trimester: Avoid use as skin absorption increases; no direct evidence of harm but theoretical risk. Topical tretinoin is contraindicated in pregnancy. |
■ FDA Black Box Warning
Embry-fetal toxicity: RETIN-A-MICRO is contraindicated in pregnancy. There is an increased risk of fetal harm if administered to pregnant women. Pregnancy must be excluded before starting therapy and effective contraception used during treatment.
| Serious Effects |
["Known hypersensitivity to tretinoin or any component of the formulation","Pregnancy (FDA Pregnancy Category C; abortifacient effects have been reported)"]
| Precautions | ["Risk of severe skin irritation, including erythema, peeling, and burning sensation; avoid concurrent use with other topical irritants or medicated cosmetics. Advise patients to use sunscreen and protective clothing due to increased susceptibility to sunburn. Avoid exposure to sunlight, sunlamps, and extreme wind or cold. May cause temporary increase in acne lesions during initial therapy (acne flare)."] |
Loading safety data…
| Fetal Monitoring | Monitor pregnancy status: confirm negative pregnancy test before initiation and monthly thereafter. Ultrasound for fetal development if exposure occurs during pregnancy. Assess for local skin reactions (erythema, peeling) in mother; no fetal monitoring required unless systemic absorption suspected. |
| Fertility Effects | No human studies; animal studies show no adverse effects on fertility at topical doses. No known impact on gametogenesis or reproductive function in humans. Theoretical risk from systemic accumulation is negligible. |